
Chemical and Pharmaceutical Bulletin p. 534 - 540 (1994)
Update date:2022-08-05
Topics:
Sakurai
Higashida
Sugano
Handa
Komai
Yagi
Nishigaki
Yabe
Systematic replacement of the P4-P2 subsites of substrate-based human immunodeficiency virus type 1 protease (HIV-1 PR) inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere (Cha-ψ[H.E.]- Ala) at positions corresponding to the scissile sites of substrates was carried out. The structure-activity relationship revealed that compounds with the combination of hydrophilic P3 and β-branched hydrophobic P2 amino acids generally showed strong inhibitory activity against HIV-1 PR. In particular, compounds 4 (Boc-Orn-Val-Cha-ψ[H.E.]-Ala-NHBu(n); Bu(n) = n- butyl, K(i) = 11 nM) and 6 (Z-Orn-Val-Cha-ψ[H.E.]-Ala-NHBu(n), K(i) = 8 nM) exhibited good enzyme selectivity, possessing no significant inhibitory activities toward closely related aspartic proteases, pepsin, cathepsin D, and renin. As a possible model system for evaluating these compounds, anti- retroviral (anti-Mo-MSV/MLV complex (Mo-MSV = Moloney murine sarcoma virus; MLV = murine leukemia virus)) activity was investigated. Both compounds were found to inhibit moderately the focus formation of Mo-MSV/MLV complex in NIH3T3 cells (compound 4, IC50 = 1.8 μM; compound 6, IC50 = 1.0 μM).
View MoreChemsky(shanghai)International Co.,Ltd.
Contact:0
Address:0
Hubei Lansun Biochemical Pharmaceutical Co., Ltd
Contact:714-6395977
Address:No. 81 Pengcheng Avenue, economic and technological development zone, Huangshi City, Hubei Province,China
AllyChem Co., Ltd., Dalian, China(BBChem)
Contact:+86-411-62313318/62313328
Address:No.5 of Jinbin Road, Jinzhou New District, Dalian City, Liaoning Province, P.R.China
Contact:+86-10-83993285
Address:Rm.1708, Haobai Tower, Building 6, No.50, North Road, West Third Ring, Haidian District, Beijing, China
Shandong Xinhua Pharmaceutical Co.,Ltd
website:http://www.xhzy.com
Contact:+86-533-2196801
Address:1 lutai road,zhangdian dis,Zibo City
Doi:10.1002/jhet.5570450407
(2008)Doi:10.1039/b311281k
(2003)Doi:10.1039/c3ra45036h
(2014)Doi:10.1002/jlac.199719970221
(1997)Doi:10.1002/ejoc.200800284
(2008)Doi:10.1016/j.bmc.2018.09.005
(2018)